Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis... Show more
Eledon Pharmaceuticals has traded in a relatively tight range in recent weeks, with shares hovering in the low-$2 zone. The stock closed near $2.41 in late October, down about 8.7% from roughly $2.64 about 30 days earlier. That muted move reflects the typical pattern of a development-stage biotech trading on clinical news flow and financing considerations rather than on broad index momentum.
Like much of the small-cap biotech sector, ELDN remains sensitive to sentiment around clinical data readouts, regulatory milestones, and capital-raising risk. With no approved products generating revenue, the investment thesis is anchored almost entirely on the progress of tegoprubart through late-stage development.
Headquartered in Irvine, California, Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immune-modulating therapies for life-threatening conditions. Its lead investigational product is tegoprubart (formerly AT-1501), a humanized monoclonal antibody that targets CD40 Ligand (CD40L), a well-validated biological pathway involved in both adaptive and innate immune activation.
The company's most advanced program is in kidney allograft transplantation, where tegoprubart is designed to prevent organ rejection while potentially avoiding the kidney toxicity associated with calcineurin inhibitors such as tacrolimus, today's standard of care. Eledon is also studying tegoprubart in islet cell transplantation for patients with type 1 diabetes, in xenotransplantation, in liver transplantation, and in amyotrophic lateral sclerosis (ALS).
Investors follow ELDN because the CD40L mechanism has broad therapeutic potential, and a differentiated safety profile versus calcineurin inhibitors could represent a meaningful advance in transplantation, a market with significant unmet need for long-term immunosuppression.
The most significant verified developments over the past 30 days center on tegoprubart's expanding clinical footprint. In early September, the company announced the submission of an Investigational New Drug (IND) application for a registrational study of tegoprubart in islet cell transplantation for type 1 diabetes, alongside the first patients enrolled in multiple transplant programs. Eledon also reaffirmed plans to initiate the Phase 3 LEGACY kidney transplantation trial in the fourth quarter of 2026.
Earlier data disclosures have reinforced the scientific narrative. Updated Phase 2 BESTOW results showed that participants treated with tegoprubart maintained significantly higher kidney function, measured by mean eGFR, versus tacrolimus through 24 months, with no rejections beyond six months in the tegoprubart arm. The FDA has also granted Fast Track designation to tegoprubart for prevention of rejection in kidney transplantation.
Despite this pipeline progress, the stock has remained range-bound, a reminder that clinical-stage valuations are also shaped by funding needs, cash runway, and the timing of data readouts rather than milestones alone.
Tickeron's Trending AI Robots page highlights a curated selection of algorithmic trading strategies that are currently attracting the most attention. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section, making it a useful starting point for traders evaluating systematic approaches. The featured bots differ in strategy, timeframe, and performance metrics, ranging from short-term momentum models to longer-horizon trend systems. For investors who prefer a data-driven, rules-based perspective alongside traditional fundamental research, exploring these tools can add another layer of market context.
The primary catalyst ahead is the initiation of the global Phase 3 LEGACY trial in kidney transplantation, expected in the fourth quarter of 2026. The trial is anticipated to enroll approximately 600 patients with a primary endpoint of non-inferiority versus tacrolimus based on a composite of biopsy-proven acute rejection, graft loss, and death. Progress toward this milestone, and subsequent enrollment updates, will be closely watched.
Investors should also monitor additional long-term data from the Phase 1b and Phase 2 BESTOW studies, FDA regulatory guidance on the path to market in islet cell transplantation and xenotransplantation, and updates from investigator-led studies. As with any pre-revenue biotech, capital position and cash runway remain important considerations, as does the broader risk appetite for small-cap clinical-stage companies. These factors will likely shape the stock's trajectory more than day-to-day price fluctuations.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ELDN moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 41 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The 10-day RSI Indicator for ELDN moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 22 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ELDN as a result. In 70 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for ELDN turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The 10-day moving average for ELDN crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELDN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ELDN entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELDN advanced for three days, in 219 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
ELDN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ELDN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.412) is normal, around the industry mean (3.592). P/E Ratio (-2.894) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELDN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of pharmaceuticals
Industry Biotechnology